IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes.

"Declarations Ethics approval and consent to participateThe study was approved by the Ethical Committee on Medical Research at Institute of Hematology and Blood Disease Hospital. Patient consentOral or written informed consent was obtained for each patient. Competing interestsRPG is a consultant to NexImmune Inc. Nanexa Pharma, Ascentage Pharm Group and Antengene Biotech LLC, Medical Director of FFF Enterprises Inc.; Partner in AZAC Inc.; Board of Directors of Russian Foundation for Cancer Research Support and Scientific Advisory Board: StemRad Ltd. Competing interests RPG is a consultant to NexImmune Inc. Nanexa Pharma, Ascentage Pharm Group and Antengene Biotech LLC, Medical Director of FFF Enterprises Inc.; Partner in AZAC Inc.; Board of Directors of Russian Foundation for Cancer Research Support and Scientific Advisory Board: StemRad Ltd."

"Funding Supported, in part, by the National Natural Science Fund (Nos. 81530008 and 81870104), CAMS Initiative Fund for Medical Sciences (Nos. 2016-I2M-1–001 and 2020-I2M-C&T-A-020 and 2020-I2M-C&T-B-090) and Haihe Laboratory of Cell Ecosystem Innovation Fund (HH22KYZX0033). RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Centre and the Ministry of Science and Technology of China (84000–51200002)."